Dr. Dangs Central Lab offers specialized bacteriophage susceptibility testing supported by advanced laboratory infrastructure, standardized methodologies, and trained technical expertise. These services address the growing clinical interest in phage therapy, particularly for multidrug-resistant infections such as chronic urinary tract infections and prostatitis.
Within a central laboratory framework, testing workflows are designed to ensure scientific rigor and reproducibility. This includes controlled pre-analytical handling, extended incubation protocols for slow-growing pathogens, and a structured two-step process comprising culture and antimicrobial sensitivity testing followed by bacteriophage susceptibility assessment. Testing is performed by trained personnel using validated equipment, dual plate readings, and routine quality checks, including batch verification against reference strains.
In addition to analytical testing, our central lab provides end-to-end sample management and works in close collaboration with clinicians and international phage therapy partners to support compassionate use and investigational programs. This integrated model enables reliable, scalable, and cost-effective phage susceptibility testing for complex clinical applications.
The laboratory has also supported an international sponsor-led clinical trial in diabetic foot infections, with a focus on correlating bacteriophage susceptibility patterns with clinical outcomes in diabetic patients.
Download Brochure
